Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer.
Conclusion: Incidence of grade ≥2 RP was 36% after CCRT followed by durvalumab for LA-NSCLC, but did not significantly differ from those of patients treated with CCRT alone. Lung dose-volume parameters were significantly correlated with RP.
PMID: 32529055 [PubMed]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Saito S, Abe T, Kobayashi N, Aoshika T, Ryuno Y, Igari M, Hirai R, Kumazaki Y, Miura Y, Kaira K, Kagamu H, Noda SE, Kato S Tags: Clin Transl Radiat Oncol Source Type: research